Vyne Therapeutics Inc (VYNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has a cash flow conversion efficiency ratio of -0.136x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($27.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vyne Therapeutics Inc for the company's overall valuation and market capitalisation.
Vyne Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyne Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Vyne Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Renewables Infrastructure Grp
LSE:TRIG
|
0.022x |
|
Duckshin Housing Co. Ltd
KQ:090410
|
-0.080x |
|
Inalways
TWO:5398
|
0.080x |
|
Next Hydrogen Solutions Inc.
V:NXH
|
-0.339x |
|
Associated Industries China Inc
TW:9912
|
0.069x |
|
Accent Resources NL
AU:ACS
|
-0.036x |
|
Mgenplus Co. Ltd.
KQ:032790
|
-0.049x |
|
Brill Shoe Industries Ltd
TA:BRIL
|
0.005x |
Annual Cash Flow Conversion Efficiency for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Vyne Therapeutics Inc from 2015 to 2025. View Vyne Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.77 Million | $-33.12 Million | -1.193x | -82.91% |
| 2024-12-31 | $52.09 Million | $-33.97 Million | -0.652x | -128.39% |
| 2023-12-31 | $88.73 Million | $-25.34 Million | -0.286x | +69.48% |
| 2022-12-31 | $31.20 Million | $-29.20 Million | -0.936x | +19.25% |
| 2021-12-31 | $48.64 Million | $-56.37 Million | -1.159x | +68.30% |
| 2020-12-31 | $37.49 Million | $-137.08 Million | -3.656x | -284.75% |
| 2019-12-31 | $68.51 Million | $-65.10 Million | -0.950x | -134.94% |
| 2018-12-31 | $130.38 Million | $-52.73 Million | -0.404x | -181.67% |
| 2017-12-31 | $-57.03 Million | $-28.25 Million | 0.495x | +536.45% |
| 2016-12-31 | $-29.44 Million | $-2.29 Million | 0.078x | -70.32% |
| 2015-12-31 | $-15.95 Million | $-4.18 Million | 0.262x | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more